Clinical trials: Influenza, completed
Influenza, Collaboration
Collaborative Efforts to Increase Flu Vaccination
Beginning with the 2009-2010 season, influenza vaccine is universally recommended for children age 6 months to 18 years old, placing extra burden on health care providers across the U.S.
- Trial name
- CollabFlu (NCT01403649)
- Testing
- Private/public collaboration to increase flu vaccination, Usual care
- Where
- 27 sites in United States
- Volunteers
- 117,175 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00319098
- Testing
- Adjuvanted pandemic influenza candidate vaccine, Fluarix
- Where
- 40 sites in Estonia, France and 5 more
- Volunteers
- 5,075 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccines, Influenza, Human
Financing Strategies of Influenza Vaccination in China
This trial focuses on influenza vaccination among three recommended groups in China. Data concerning the economic burden of influenza-like illness (ILI), vaccine hesitancy, discrete choice experiment, immunization records and…
- Conditions
- Influenza Vaccines, Influenza, Human, Cost of Illness, Health Knowledge, Attitudes, Practice
- Trial name
- NCT04038333
- Testing
- No intervention
- Where
- 3 sites in China
- Volunteers
- 13,542 people, healthy volunteers welcome
- Sponsor
- Peking University
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A\&B Panel Self Test in the hands of patients/lay-users.
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT06124638
- Testing
- Panbio™ COVID-19/Flu A&B Panel
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- Abbott Rapid Dx
Influenza
A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years
Routine annual influenza vaccination is recommended for all persons aged≥6 months who do not have contraindications. For those aged 6 monthsthrough 8 years who have previously received ≥2 total doses of trivalent orquadrivalent…
- Trial name
- NCT05313893
- Testing
- Quadrivalent influenza vaccine
- Where
- China
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or…
- Trial name
- NCT00959049
- Testing
- CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
- Where
- 23 sites in United States
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- Seqirus
Human Influenza
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each influenza…
- Trial name
- NCT01885117
- Testing
- TIVf
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Combining Entertainment & Influenza Education for Pediatric Patients
The investigators have developed an influenza-vaccination-education-study-program that will involve the use of an animated influenza vaccine-based computer program (videogame) that is designed from the investigator's own…
- Trial name
- NCT01788514
- Testing
- Videogame
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Influenza
Influenza Reminder Text-Messaging
Through a large, population-level quality improvement effort within the Children's Hospital of Philadelphia Care Network, we will evaluate text message reminders on flu vaccination rates for both patients with and without a…
- Trial name
- NCT06587984
- Testing
- Text message reminder
- Where
- United States
- Volunteers
- 228,361 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Influenza
Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years
The purpose of this study is to show that vaccination with a single dose of GSK Biologicals' pandemic H1N1 vaccine results in an immune response that meets or exceeds European Medicines Agency (EMEA) Committee for Medicinal…
- Trial name
- NCT01035749
- Testing
- GSK Biologicals' Influenza investigational vaccine GSK2340274A, GSK Biologicals' Influenza investigational vaccine GSK2340273A
- Where
- 9 sites in Estonia, Slovakia
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunology, Nephrology
Immune Response to Influenza Vaccine in ESRD Patients
On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients.
- Trial name
- NCT04122222
- Testing
- Influenza vaccine
- Volunteers
- 60 people
- Sponsor
- Mahidol University
Healthy
Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route
Background: It is well established that live attenuated organisms can be highly effective vaccines, immune responses elicited can often be of greater magnitude and of longer duration than those produced by non-living antigens and…
- Trial name
- NCT01488188
- Testing
- Influenza vaccine
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
The primary objective of this study was to perform a variety of immunological assays on blood, serum, nasal wash samples, and cells obtained from healthy adult subjects for the purpose of developing assays for application in the…
- Trial name
- NCT00192231
- Testing
- CAIV-T
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Household Influenza Transmission Study
The purpose of this study is to determine whether nonpharmaceutical interventions (i.e., handwashing and masks) reduce secondary transmission of influenza in households.
- Trial name
- HITS (NCT01251679)
- Testing
- Hand washing, Hand washing and surgical mask
- Where
- Thailand
- Volunteers
- 2,920 people
- Sponsor
- Centers for Disease Control and Prevention
Swine-Origin Influenza A H1N1 Virus
Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine
This is to evaluate safety of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese subjects.
- Trial name
- NCT01098786
- Testing
- Cell-derived A/H1N1 influenza HA vaccine
- Where
- Japan
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
- Trial name
- NCT01992094
- Testing
- QIVc, TIV1c, TIV2c
- Where
- 40 sites in United States
- Volunteers
- 2,680 people
- Sponsor
- Novartis Vaccines
Influenza Virus Infection, Influenza-like Illness
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
The purpose of this study is to determine the degree of indirect benefits to family members and classmates resulting from administration of influenza vaccine to children.
- Conditions
- Influenza Virus Infection, Influenza-like Illness, Acute Respiratory Infection
- Trial name
- NCT00981513
- Testing
- Trivalent live attenuated seasonal influenza vaccine, Monovalent live attenuated pandemic influenza vaccine, Saline
- Where
- Hong Kong
- Volunteers
- 6,300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season
This is a yearly licence tolerability and immunogenicity study of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/strain/0.5mL) in adult and elderly subjects to assess…
- Trial name
- NCT01649713
- Testing
- Fluval AB vaccination
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza A Virus, H7N9 Subtype
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
The purpose of this study is to evaluate the safety and immunogenicity of one dose of H7N9 pandemic live attenuated influenza vaccine (H7N9 pLAIV) followed by AS03-adjuvanted H7N9 pandemic inactivated influenza vaccine (H7N9…
- Trial name
- NCT02957656
- Testing
- H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.